Open an account

Veradermics

MANE · NYSE

$127.11+$4.83 (+3.95%)TodayMarket closed ·
Prev close $122.28

About MANE

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. The company is headquartered in New Haven, Connecticut and currently employs 21 full-time employees. The company went IPO on 2026-02-04. The firm is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The firm is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The firm is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

Employees
21
Headquarters
New Haven, Connecticut
Listed
Feb 4, 2026
Sector
Health Care
Industry
Pharmaceuticals
Website
veradermics.com

MANE key statistics

Market cap
5.31B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
939.09K
Volume
1.07M
Open price
$120.62
High today
$130.11
Low today
$113.52
52 Week high
$136.72
52 Week low
$32.00

Veradermics (MANE) at a glance

Veradermics (MANE) last traded at $127.11, with a market cap of 5.31B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $113.52 and $130.11. The current price is 12.0% above the day's low and 2.3% below its high.

Volume so far is 1.07M shares, in line with the average of 939.09K shares a day.

Over the past year Veradermics has ranged from $32.00 to $136.72, and now sits 91% of the way up that range.

Veradermics met or beat analyst EPS estimates in 1 of the last 2 quarters. In Q2 FY26 it reported -$0.58 per share against an estimate of -$0.6605.

The average analyst price target is $166.77, 31.2% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $166.77
Low
$136.35
Now
$127.11
High
$191.10

MANE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 2 quarters, by 12.2% on average.

  1. Q1 FY26: reported -$1.32 per share against an estimate of -$0.6676
  2. Q2 FY26: reported -$0.58 per share against an estimate of -$0.6605

MANE news

  • Vandana Singh

    Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough

  • Avi Kapoor

    Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

  • Press releaseBusiness Wire

    Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss

  • Press releaseBusiness Wire

    Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

  • Press releaseBusiness Wire

    Veradermics to Present at Upcoming September Investor Conferences

  • Press releaseBusiness Wire

    Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

  • Press releaseBusiness Wire

    Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

  • Vandana Singh

    Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Similar companies

Companies in the same industry as Veradermics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.